Development and characterization of recombinant antibody Fragments that recognize and neutralize in vitro Stx2 toxin from shiga toxin-producing escherichia coli

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorLuz, Daniela-
Autor(es): dc.creatorChen, Gang-
Autor(es): dc.creatorMaranhão, Andrea Queiroz-
Autor(es): dc.creatorRocha, Leticia Barboza-
Autor(es): dc.creatorSidhu, Sachdev-
Autor(es): dc.creatorPiazza, Roxane Maria Fontes-
Data de aceite: dc.date.accessioned2021-10-14T18:01:43Z-
Data de disponibilização: dc.date.available2021-10-14T18:01:43Z-
Data de envio: dc.date.issued2017-02-06-
Data de envio: dc.date.issued2017-02-06-
Data de envio: dc.date.issued2015-03-
Fonte completa do material: dc.identifierhttp://repositorio.unb.br/handle/10482/22422-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1371/journal.pone.0120481-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/621872-
Descrição: dc.descriptionBackground: Stx toxin is a member of the AB5 family of bacterial toxins: the active A subunit has N-glycosidase activity against 28S rRNA, resulting in inhibition of protein synthesis in eukaryotic cells, and the pentamer ligand B subunits (StxB) bind to globotria(tetra)osylceramide receptors (Gb3/Gb4) on the cell membrane. Shiga toxin-producing Escherichia coli strains (STEC) may produce Stx1 and/or Stx2 and variants. Strains carrying Stx2 are considered more virulent and related to the majority of outbreaks, besides being usually associated with hemolytic uremic syndrome in humans. The development of tools for the detection and/or neutralization of these toxins is a turning point for early diagnosis and therapeutics. Antibodies are an excellent paradigm for the design of high-affinity, protein-based binding reagents used for these purposes. Methods: and Findings In this work, we developed two recombinant antibodies; scFv fragments from mouse hybridomas and Fab fragments by phage display technology using a human synthetic antibody library. Both fragments showed high binding affinity to Stx2, and they were able to bind specifically to the GKIEFSKYNEDDTF region of the Stx2 B subunit and to neutralize in vitro the cytotoxicity of the toxin up to 80%. Furthermore, the scFv fragments showed 79% sensitivity and 100% specificity in detecting STEC strains by ELISA. Conclusion: In this work, we developed and characterized two recombinant antibodies against Stx2, as promising tools to be used in diagnosis or therapeutic approaches against STEC, and for the first time, we showed a human monovalent molecule, produced in bacteria, able to neutralize the cytotoxicity of Stx2 in vitro.-
Formato: dc.formatapplication/pdf-
Publicador: dc.publisherPlos One-
Direitos: dc.rightsAcesso Aberto-
Direitos: dc.rightsCopyright: © 2015 Luz et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Fonte: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0120481. Acesso em: 12 dez. 2016.-
Palavras-chave: dc.subjectAnticorpos-
Palavras-chave: dc.subjectDiagnóstico-
Palavras-chave: dc.subjectToxinas-
Título: dc.titleDevelopment and characterization of recombinant antibody Fragments that recognize and neutralize in vitro Stx2 toxin from shiga toxin-producing escherichia coli-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:UNB

Não existem arquivos associados a este item.